Humoral Responses to SARS-CoV-2 Vaccination in Rituximab-Treated Patients Depend on Peripheral B Cell Re-population Rather Than the Timings of the Dosing
Open accessResearch articleFirst published online March, 2022
Humoral Responses to SARS-CoV-2 Vaccination in Rituximab-Treated Patients Depend on Peripheral B Cell Re-population Rather Than the Timings of the Dosing